As HCC is a hypervascular cancer, it was theorized that the efficacy of sorafenib is primarily attributable to its inhibition of tumor angiogenesis by targeting VEGFR and PDGFR, and partly to the inhibition of Raf [40]. Here, RAF1 is linked to hepatocellular carcinoma.